PMC:7080117 / 9235-10281
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"227","span":{"begin":755,"end":773},"obj":"Gene"},{"id":"228","span":{"begin":775,"end":779},"obj":"Gene"},{"id":"229","span":{"begin":55,"end":63},"obj":"Species"},{"id":"230","span":{"begin":73,"end":80},"obj":"Species"},{"id":"231","span":{"begin":135,"end":138},"obj":"Species"},{"id":"232","span":{"begin":150,"end":155},"obj":"Species"},{"id":"233","span":{"begin":214,"end":221},"obj":"Species"},{"id":"234","span":{"begin":988,"end":998},"obj":"Species"},{"id":"235","span":{"begin":205,"end":213},"obj":"Disease"},{"id":"236","span":{"begin":294,"end":306},"obj":"Disease"},{"id":"237","span":{"begin":318,"end":326},"obj":"Disease"},{"id":"238","span":{"begin":336,"end":358},"obj":"Disease"},{"id":"239","span":{"begin":368,"end":405},"obj":"Disease"},{"id":"240","span":{"begin":415,"end":427},"obj":"Disease"},{"id":"241","span":{"begin":483,"end":499},"obj":"Disease"},{"id":"242","span":{"begin":511,"end":516},"obj":"Disease"},{"id":"243","span":{"begin":557,"end":576},"obj":"Disease"},{"id":"244","span":{"begin":585,"end":592},"obj":"Disease"},{"id":"245","span":{"begin":643,"end":651},"obj":"Disease"},{"id":"246","span":{"begin":661,"end":669},"obj":"Disease"},{"id":"247","span":{"begin":679,"end":685},"obj":"Disease"},{"id":"249","span":{"begin":8,"end":15},"obj":"Species"}],"attributes":[{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"Gene:1401"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"Gene:11343"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"Tax:9606"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"Tax:9606"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"Tax:9606"},{"id":"A232","pred":"tao:has_database_id","subj":"232","obj":"Tax:9606"},{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"Tax:9606"},{"id":"A234","pred":"tao:has_database_id","subj":"234","obj":"Tax:2697049"},{"id":"A235","pred":"tao:has_database_id","subj":"235","obj":"MESH:D007239"},{"id":"A236","pred":"tao:has_database_id","subj":"236","obj":"MESH:D006973"},{"id":"A237","pred":"tao:has_database_id","subj":"237","obj":"MESH:D003920"},{"id":"A238","pred":"tao:has_database_id","subj":"238","obj":"MESH:D002318"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"MESH:D029424"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"MESH:D014376"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"MESH:D051271"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:D003371"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"MESH:C000657245"},{"id":"A244","pred":"tao:has_database_id","subj":"244","obj":"MESH:D063806"},{"id":"A245","pred":"tao:has_database_id","subj":"245","obj":"MESH:D006261"},{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"MESH:D003967"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"MESH:D009325"},{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T34","span":{"begin":528,"end":534},"obj":"Body_part"},{"id":"T35","span":{"begin":609,"end":615},"obj":"Body_part"},{"id":"T36","span":{"begin":766,"end":773},"obj":"Body_part"},{"id":"T37","span":{"begin":866,"end":876},"obj":"Body_part"}],"attributes":[{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma312401"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma62852"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T35","span":{"begin":528,"end":534},"obj":"Body_part"},{"id":"T36","span":{"begin":609,"end":615},"obj":"Body_part"},{"id":"T37","span":{"begin":695,"end":700},"obj":"Body_part"}],"attributes":[{"id":"A35","pred":"uberon_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"},{"id":"A36","pred":"uberon_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A37","pred":"uberon_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/UBERON_0000172"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T49","span":{"begin":294,"end":306},"obj":"Disease"},{"id":"T50","span":{"begin":318,"end":326},"obj":"Disease"},{"id":"T51","span":{"begin":336,"end":358},"obj":"Disease"},{"id":"T52","span":{"begin":368,"end":405},"obj":"Disease"},{"id":"T53","span":{"begin":388,"end":405},"obj":"Disease"},{"id":"T54","span":{"begin":415,"end":427},"obj":"Disease"},{"id":"T55","span":{"begin":604,"end":615},"obj":"Disease"},{"id":"T56","span":{"begin":661,"end":669},"obj":"Disease"},{"id":"T57","span":{"begin":988,"end":996},"obj":"Disease"}],"attributes":[{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0018076"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0002258"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T82","span":{"begin":126,"end":128},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T83","span":{"begin":283,"end":285},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T84","span":{"begin":546,"end":548},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T85","span":{"begin":748,"end":752},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T86","span":{"begin":855,"end":857},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T87","span":{"begin":866,"end":876},"obj":"http://purl.obolibrary.org/obo/CL_0000738"},{"id":"T88","span":{"begin":1013,"end":1017},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":766,"end":773},"obj":"Chemical"},{"id":"T7","span":{"begin":1000,"end":1012},"obj":"Chemical"},{"id":"T8","span":{"begin":1008,"end":1012},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T73","span":{"begin":0,"end":54},"obj":"Sentence"},{"id":"T74","span":{"begin":55,"end":72},"obj":"Sentence"},{"id":"T75","span":{"begin":73,"end":93},"obj":"Sentence"},{"id":"T76","span":{"begin":94,"end":132},"obj":"Sentence"},{"id":"T77","span":{"begin":133,"end":147},"obj":"Sentence"},{"id":"T78","span":{"begin":148,"end":164},"obj":"Sentence"},{"id":"T79","span":{"begin":165,"end":181},"obj":"Sentence"},{"id":"T80","span":{"begin":182,"end":230},"obj":"Sentence"},{"id":"T81","span":{"begin":231,"end":256},"obj":"Sentence"},{"id":"T82","span":{"begin":257,"end":276},"obj":"Sentence"},{"id":"T83","span":{"begin":277,"end":291},"obj":"Sentence"},{"id":"T84","span":{"begin":292,"end":315},"obj":"Sentence"},{"id":"T85","span":{"begin":316,"end":333},"obj":"Sentence"},{"id":"T86","span":{"begin":334,"end":365},"obj":"Sentence"},{"id":"T87","span":{"begin":366,"end":412},"obj":"Sentence"},{"id":"T88","span":{"begin":413,"end":434},"obj":"Sentence"},{"id":"T89","span":{"begin":435,"end":454},"obj":"Sentence"},{"id":"T90","span":{"begin":455,"end":472},"obj":"Sentence"},{"id":"T91","span":{"begin":473,"end":491},"obj":"Sentence"},{"id":"T92","span":{"begin":492,"end":508},"obj":"Sentence"},{"id":"T93","span":{"begin":509,"end":525},"obj":"Sentence"},{"id":"T94","span":{"begin":526,"end":554},"obj":"Sentence"},{"id":"T95","span":{"begin":555,"end":582},"obj":"Sentence"},{"id":"T96","span":{"begin":583,"end":601},"obj":"Sentence"},{"id":"T97","span":{"begin":602,"end":624},"obj":"Sentence"},{"id":"T98","span":{"begin":625,"end":640},"obj":"Sentence"},{"id":"T99","span":{"begin":641,"end":658},"obj":"Sentence"},{"id":"T100","span":{"begin":659,"end":676},"obj":"Sentence"},{"id":"T101","span":{"begin":677,"end":692},"obj":"Sentence"},{"id":"T102","span":{"begin":693,"end":707},"obj":"Sentence"},{"id":"T103","span":{"begin":708,"end":736},"obj":"Sentence"},{"id":"T104","span":{"begin":737,"end":752},"obj":"Sentence"},{"id":"T105","span":{"begin":753,"end":799},"obj":"Sentence"},{"id":"T106","span":{"begin":800,"end":822},"obj":"Sentence"},{"id":"T107","span":{"begin":823,"end":836},"obj":"Sentence"},{"id":"T108","span":{"begin":837,"end":854},"obj":"Sentence"},{"id":"T109","span":{"begin":855,"end":863},"obj":"Sentence"},{"id":"T110","span":{"begin":864,"end":907},"obj":"Sentence"},{"id":"T111","span":{"begin":908,"end":928},"obj":"Sentence"},{"id":"T112","span":{"begin":929,"end":951},"obj":"Sentence"},{"id":"T113","span":{"begin":952,"end":971},"obj":"Sentence"},{"id":"T114","span":{"begin":972,"end":1020},"obj":"Sentence"},{"id":"T115","span":{"begin":1021,"end":1046},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}
LitCovid-PD-HP
{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":294,"end":306},"obj":"Phenotype"},{"id":"T31","span":{"begin":336,"end":358},"obj":"Phenotype"},{"id":"T32","span":{"begin":368,"end":405},"obj":"Phenotype"},{"id":"T33","span":{"begin":494,"end":499},"obj":"Phenotype"},{"id":"T34","span":{"begin":511,"end":516},"obj":"Phenotype"},{"id":"T35","span":{"begin":557,"end":564},"obj":"Phenotype"},{"id":"T36","span":{"begin":585,"end":592},"obj":"Phenotype"},{"id":"T37","span":{"begin":604,"end":615},"obj":"Phenotype"},{"id":"T38","span":{"begin":627,"end":633},"obj":"Phenotype"},{"id":"T39","span":{"begin":643,"end":651},"obj":"Phenotype"},{"id":"T40","span":{"begin":661,"end":669},"obj":"Phenotype"},{"id":"T41","span":{"begin":679,"end":685},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A34","pred":"hp_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0012378"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0003326"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0033050"},{"id":"A38","pred":"hp_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/HP_0025143"},{"id":"A39","pred":"hp_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A40","pred":"hp_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0002018"}],"text":"Table 1 Patient characteristics and laboratory results\nPatients (n = 90)\nPatient demographics\n Median age, years (range) 50 (18–86)\n Men 39 (43%)\n Women 51 (57%)\nExposure history\n Exposure to Wuhan or infected patient 86 (96%)\n Unknown exposure 4 (4%)\nComorbid conditions\n Any 45 (50%)\n Hypertension 17 (19%)\n Diabetes 5 (6%)\n Cardiovascular disease 3 (3%)\n Chronic obstructive pulmonary disease 1 (1%)\n Tuberculosis 2 (2%)\n Malignancy 2 (2%)\n Others 15 (17%)\nSigns and symptoms\n Fever 70 (78%)\n Cough 57 (63%)\n Sputum production 11 (12%)\n Fatigue weakness 19 (21%)\n Myalgia 25 (28%)\n Sore throat 23 (26%)\n Chills 6 (7%)\n Headache 4 (4%)\n Diarrhea 5 (6%)\n Nausea 5 (6%)\n Vomit 2 (2%)\n No obvious symptoms 6 (7%)\nLaboratory test\n C-reactive protein (mg/L; normal range 0–10)\n Increased 38 (42%)\n Decreased\n Normal 0 (0%)\n52 (58%)\n Leucocytes (×109/L, normal range 3.5–9.5)\n Increased 3 (3%)\n Decreased 19 (21%)\n Normal 68 (76%)\n Positive for (SARS-CoV-2) nucleic acid test by\n Real-time PCR 90 (100%)"}